Astellas Pharma US, Inc.
NEWS
The American Society of Clinical Oncology 2019 Genitourinary Cancers Symposium (ASCO GU) is being held in San Francisco from February 14-16. Ahead of the conference, several companies have announced presentations. Here’s a look at just a few.
The FDA approved Xospata for adult AML patients who have a FLT3 mutation as detected by an FDA-approved test. Of the 19,000 people in the United States who are estimated to be diagnosed with AML this year, nearly 40 percent will have a FLT3 mutation.
Nektar Therapeutics, based in San Francisco, and New York-based Pfizer are teaming up to evaluate combination regimens in several cancer settings. Those include metastatic castration-resistant prostate cancer (mCRPC) and squamous cell carcinoma of the head and heck (SCCHN).
Here’s a look at who’s making moves in the biotech and pharma world this week.
Despite the changing landscape in biopharma, many companies are still recruiting. If you’re looking to make a career change, here are 12 biopharma companies hiring on BioSpace now.
Pfizer and Astellas Pharma announced they have amended the protocols for two Phase III clinical trials, ARCHES and EMBARK, to evaluate Xtandi (enzalutamide) in hormone-sensitive prostate cancer (HSPC). Both trials will wrap sooner than planned as a result.
Japan-based Astellas plunked down nearly $109 million to snap up privately-held gene therapy company Quethera Limited and its novel treatments for glaucoma and other ocular disorders.
JOBS
IN THE PRESS